Cargando…

The Prognostic Relevance of Poly (ADP-Ribose) Polymerase Expression in Ovarian Cancer Tissue of Wild Type and BRCA-Mutation Carrier Patients

(1) Background: The mechanism of platinum resistance in ovarian cancer is not fully clarified, but the properly functioning DNA repair mechanism can counteract the effect of conventional anticancer treatment. The objective of our study was to evaluate the expression of an important DNA repair enzyme...

Descripción completa

Detalles Bibliográficos
Autores principales: Molnár, Szabolcs, Vida, Beáta, Beke, Lívia, Méhes, Gábor, Póka, Róbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835745/
https://www.ncbi.nlm.nih.gov/pubmed/33478135
http://dx.doi.org/10.3390/diagnostics11010144
_version_ 1783642594795847680
author Molnár, Szabolcs
Vida, Beáta
Beke, Lívia
Méhes, Gábor
Póka, Róbert
author_facet Molnár, Szabolcs
Vida, Beáta
Beke, Lívia
Méhes, Gábor
Póka, Róbert
author_sort Molnár, Szabolcs
collection PubMed
description (1) Background: The mechanism of platinum resistance in ovarian cancer is not fully clarified, but the properly functioning DNA repair mechanism can counteract the effect of conventional anticancer treatment. The objective of our study was to evaluate the expression of an important DNA repair enzyme, the Poly (ADP-Ribose) Polymerase (PARP) expression in epithelial ovarian cancer (EOC) tissues depending on BRCA status and to assess its relationship with platinum resistance. (2) Methods: Immunostaining to highlight PARP protein expression was performed using a rabbit polyclonal anti-PARP antibody. The intensity and distribution of immunostaining were assessed by light. Somatic BRCA1 or BRCA2 mutation carriers were identified with bidirectional sequencing of DNA from archived tumor tissue, if the test could not be performed due to technical reasons from tumor cells, the sequencing was done from peripheral blood cells to identify germline mutation carriers. The median progression-free survival (PFS) was generated for each semiquantitative group of PARP expression among chemotherapy-naive cases at the time of PARP immunohistochemistry. (3) Results: In the overall population, negative PARP immunohistochemistry predicted significant PFS (20.1 vs. 11.9 months, p = 0.001) and OS (49 vs. 114 months, p = 0.014) benefit. Genotype-stratified subgroup analysis in BRCA-negative cases confirmed the role of PARP positivity indicating an unfavorable prognosis in the entire population (relapsed 73.91% vs. 92%; OR: 4.06; p = 0.04). In the cases of the subgroup carrying the BRCA mutation, the presence of PARP expression was not associated with less favorable relapse rates, but with marginal significance for overall survival predicted a lower chance of survival (OS more than 32 months 72.73% vs. 35%; OR: 0.2; p = 0.05). (4) Conclusion: The BRCA wild type patients with strong expression of PARP enzymes before the first set of chemotherapy have a poor prognosis.
format Online
Article
Text
id pubmed-7835745
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-78357452021-01-27 The Prognostic Relevance of Poly (ADP-Ribose) Polymerase Expression in Ovarian Cancer Tissue of Wild Type and BRCA-Mutation Carrier Patients Molnár, Szabolcs Vida, Beáta Beke, Lívia Méhes, Gábor Póka, Róbert Diagnostics (Basel) Article (1) Background: The mechanism of platinum resistance in ovarian cancer is not fully clarified, but the properly functioning DNA repair mechanism can counteract the effect of conventional anticancer treatment. The objective of our study was to evaluate the expression of an important DNA repair enzyme, the Poly (ADP-Ribose) Polymerase (PARP) expression in epithelial ovarian cancer (EOC) tissues depending on BRCA status and to assess its relationship with platinum resistance. (2) Methods: Immunostaining to highlight PARP protein expression was performed using a rabbit polyclonal anti-PARP antibody. The intensity and distribution of immunostaining were assessed by light. Somatic BRCA1 or BRCA2 mutation carriers were identified with bidirectional sequencing of DNA from archived tumor tissue, if the test could not be performed due to technical reasons from tumor cells, the sequencing was done from peripheral blood cells to identify germline mutation carriers. The median progression-free survival (PFS) was generated for each semiquantitative group of PARP expression among chemotherapy-naive cases at the time of PARP immunohistochemistry. (3) Results: In the overall population, negative PARP immunohistochemistry predicted significant PFS (20.1 vs. 11.9 months, p = 0.001) and OS (49 vs. 114 months, p = 0.014) benefit. Genotype-stratified subgroup analysis in BRCA-negative cases confirmed the role of PARP positivity indicating an unfavorable prognosis in the entire population (relapsed 73.91% vs. 92%; OR: 4.06; p = 0.04). In the cases of the subgroup carrying the BRCA mutation, the presence of PARP expression was not associated with less favorable relapse rates, but with marginal significance for overall survival predicted a lower chance of survival (OS more than 32 months 72.73% vs. 35%; OR: 0.2; p = 0.05). (4) Conclusion: The BRCA wild type patients with strong expression of PARP enzymes before the first set of chemotherapy have a poor prognosis. MDPI 2021-01-19 /pmc/articles/PMC7835745/ /pubmed/33478135 http://dx.doi.org/10.3390/diagnostics11010144 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Molnár, Szabolcs
Vida, Beáta
Beke, Lívia
Méhes, Gábor
Póka, Róbert
The Prognostic Relevance of Poly (ADP-Ribose) Polymerase Expression in Ovarian Cancer Tissue of Wild Type and BRCA-Mutation Carrier Patients
title The Prognostic Relevance of Poly (ADP-Ribose) Polymerase Expression in Ovarian Cancer Tissue of Wild Type and BRCA-Mutation Carrier Patients
title_full The Prognostic Relevance of Poly (ADP-Ribose) Polymerase Expression in Ovarian Cancer Tissue of Wild Type and BRCA-Mutation Carrier Patients
title_fullStr The Prognostic Relevance of Poly (ADP-Ribose) Polymerase Expression in Ovarian Cancer Tissue of Wild Type and BRCA-Mutation Carrier Patients
title_full_unstemmed The Prognostic Relevance of Poly (ADP-Ribose) Polymerase Expression in Ovarian Cancer Tissue of Wild Type and BRCA-Mutation Carrier Patients
title_short The Prognostic Relevance of Poly (ADP-Ribose) Polymerase Expression in Ovarian Cancer Tissue of Wild Type and BRCA-Mutation Carrier Patients
title_sort prognostic relevance of poly (adp-ribose) polymerase expression in ovarian cancer tissue of wild type and brca-mutation carrier patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835745/
https://www.ncbi.nlm.nih.gov/pubmed/33478135
http://dx.doi.org/10.3390/diagnostics11010144
work_keys_str_mv AT molnarszabolcs theprognosticrelevanceofpolyadpribosepolymeraseexpressioninovariancancertissueofwildtypeandbrcamutationcarrierpatients
AT vidabeata theprognosticrelevanceofpolyadpribosepolymeraseexpressioninovariancancertissueofwildtypeandbrcamutationcarrierpatients
AT bekelivia theprognosticrelevanceofpolyadpribosepolymeraseexpressioninovariancancertissueofwildtypeandbrcamutationcarrierpatients
AT mehesgabor theprognosticrelevanceofpolyadpribosepolymeraseexpressioninovariancancertissueofwildtypeandbrcamutationcarrierpatients
AT pokarobert theprognosticrelevanceofpolyadpribosepolymeraseexpressioninovariancancertissueofwildtypeandbrcamutationcarrierpatients
AT molnarszabolcs prognosticrelevanceofpolyadpribosepolymeraseexpressioninovariancancertissueofwildtypeandbrcamutationcarrierpatients
AT vidabeata prognosticrelevanceofpolyadpribosepolymeraseexpressioninovariancancertissueofwildtypeandbrcamutationcarrierpatients
AT bekelivia prognosticrelevanceofpolyadpribosepolymeraseexpressioninovariancancertissueofwildtypeandbrcamutationcarrierpatients
AT mehesgabor prognosticrelevanceofpolyadpribosepolymeraseexpressioninovariancancertissueofwildtypeandbrcamutationcarrierpatients
AT pokarobert prognosticrelevanceofpolyadpribosepolymeraseexpressioninovariancancertissueofwildtypeandbrcamutationcarrierpatients